GEN Exclusives

More »

Assay Tutorials

More »
May 15, 2010 (Vol. 30, No. 10)

iPSC-Derived Human Cardiomyocytes

Stem Cell Technology Can Facilitate Quick & Early Failure of Toxic or Ineffective NCEs

  • Summary

    Cellular Dynamics has developed a highly standardized, scalable process to manufacture human iPSC-derived cardiomyocytes. Using this process, we can produce the industrialized quantities of human cardiomyocytes needed by the pharmaceutical industry for drug toxicity testing.

    These cardiomyocytes demonstrate typical physiological properties and show appropriate sensitivity to cardiotoxic compounds expected of human cardiomyocytes. The ability to consistently produce large numbers of high-quality and high-purity cardiomyocytes offers the pharmaceutical industry a new tool to better predict the cardiotoxicity of new drug candidates.

    It is expected that these cells will allow pharmaceutical companies to more efficiently select drug candidates while reducing the likelihood that cardiotoxic activity of these compounds will manifest themselves late in development or after regulatory approval and market launch.



Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Alzheimer's Therapies

Do you think an effective treatment for Alzheimer’s will be found within the next 10–15 years?